Phase III XELOX trial in metastatic colorectal cancer meets primary endpoints

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2006年 / 20卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1871 / 1872
页数：2
相关论文
共 50 条
  • [1] Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
    Van Cutsem, Eric
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Sargent, Daniel J.
    Cihon, Frank
    Wagner, Andrea
    Laurent, Dirk
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: results of a phase II trial
    Bendell, J.
    Yu, D.
    Hurwitz, H.
    Morse, M.
    Blobe, G.
    Gockerman, J.
    Odogwu, L.
    Mahon, M.
    Truax, R.
    Fernando, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 189
  • [3] A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer
    Mackay, H
    Hedley, D
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Degendorfer, P
    Tsao, MS
    Nicklee, T
    Birle, D
    Wright, J
    Siu, L
    Moore, M
    Oza, A
    CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5526 - 5533
  • [4] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
  • [5] A Randomised Controlled PhaseⅡTrial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
    Jing Lv
    Ning Liu
    Ke-wei Liu
    Ai-ping Ding
    Hao Wang
    Wen-sheng Qiu
    Cancer Biology & Medicine, 2012, (02) : 111 - 114
  • [6] Phase III randomized trial comparing short-term infusion of oxaliplatin and capecitabine (Xelox30) with chronomodulated (Xelox30) in patients with advanced and/or metastatic colorectal cancer
    Nafea, M. Q.
    Mahmoud, S. H.
    Gado, N. M.
    Hafeez, Z. M. Abdel
    El-Ghonemy, K. K-E.
    ANNALS OF ONCOLOGY, 2020, 31 : S429 - S429
  • [7] A Randomised Controlled PhaseⅡTrial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
    Jing Lv
    Ning Liu
    Ke-wei Liu
    Ai-ping Ding
    Hao Wang
    Wen-sheng Qiu
    Cancer Biology & Medicine, 2012, 9 (02) : 111 - 114
  • [8] Primary endpoints of phase III trials for older patients with cancer
    Mizutani, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1187 - S1187
  • [9] Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer: Analysis of bevacizumab in combination with xelox or FOLFOX4
    Saltz, L.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, R.
    Cassidy, J.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [10] A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer
    Yalcin, S.
    Uslu, R.
    Dane, F.
    Yilmaz, U.
    Zengin, N.
    Buyukunal, E.
    Buyukberber, S.
    Camci, C.
    Sencan, O.
    Kilickap, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345